Showing 244 results

Filters Content type: News, Editors' picks, About HIV Topic: Injectable & long-acting HIV treatment

Research into injectable medications and other innovative forms of HIV treatment. It is hoped that they may only need to be taken every few weeks or months, rather than daily.

 

HIV treatment

Lenacapavir

About HIV
March 2023
Injectable & long-acting HIV treatment

Lenacapavir plus broadly neutralising antibodies may offer twice-yearly treatment option

News
28 February 2023
Injectable & long-acting HIV treatment

CROI 2023: Lenacapavir and two broadly neutralising antibodies for treatment Video

February 2023
Injectable & long-acting HIV treatment

San Francisco shows that long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression

News
23 February 2023
Injectable & long-acting HIV treatment

ViiV Healthcare announces positive data demonstrating long-acting injectable Cabenuva (cabotegravir, rilpivirine) is as effective as daily oral Biktarvy (BIC/FTC/TAF) for the treatment of HIV-1

Editor's pick
ViiV press release
23 February 2023
Weight gain & lipodystrophy

Switching to injectable cabotegravir and rilpivirine rarely affects body weight

News
23 February 2023
Injectable & long-acting HIV treatment

I Stopped Taking My HIV Pills

Editor's pick
POZ
20 January 2023
Injectable & long-acting HIV treatment

Study Bite: Despite Initial Interest, Many Don’t Switch to LA-ART

Editor's pick
TheBodyPro
20 January 2023
Injectable & long-acting HIV treatment

Injectable HIV treatment offers hope to Ugandan patients

Editor's pick
Reuters
26 December 2022
Injectable & long-acting HIV treatment

FDA Approves New HIV Drug for Adults with Limited Treatment Options

Editor's pick
FDA
22 December 2022
Injectable & long-acting HIV treatment

The people who need injectable HIV drugs most are the ones who can’t get them, BHIVA told

News
7 December 2022
Injectable & long-acting HIV treatment

Pregnancy Outcomes on Long-Acting Antiretroviral

Editor's pick
Medscape (requires free registration)
6 December 2022
Injectable & long-acting HIV treatment

Botswana Introduces Injectable Antiretrovirals for HIV Treatment

Editor's pick
AllAfrica
23 November 2022
Antibody-based treatment

Do broadly neutralising antibodies really have a future in treating HIV?

News
11 November 2022
Injectable & long-acting HIV treatment

Lenacapavir Shows Continued Promise for People With Drug-Resistant HIV

Editor's pick
POZ
10 November 2022
Injectable & long-acting HIV treatment

HIV Glasgow 2022: Injectable cabotegravir and rilpivirine Video

November 2022
Injectable & long-acting HIV treatment

Who is at risk of injectable treatment failure?

News
1 November 2022
Injectable & long-acting HIV treatment

‘Real world’ injectable treatment halves patient dissatisfaction, with only two viral failures in first six months

News
1 November 2022
People with limited treatment options

FDA Approves Trogarzo for 30-Second IV Push, Simplifying HIV Treatment for Heavily Treatment-Experienced People

Editor's pick
Infectious Disease Special Edition
5 October 2022
Drug interactions & pharmacokinetics

Low levels of RPV-LA might explain failure with injectable ART despite perfect adherence

Editor's pick
i-Base
3 October 2022
Injectable & long-acting HIV treatment

Compassionate Use of Long-Acting Cabotegravir Plus Rilpivirine in HIV

Editor's pick
Infectious Disease Advisor
26 September 2022
New & experimental HIV treatments

European Commission approves first twice-yearly HIV medication

News
25 August 2022
Injectable & long-acting HIV treatment

UNAIDS responds to EU approval of a long acting HIV treatment option: “To end AIDS, share technology.”

Editor's pick
UNAIDS
23 August 2022
Injectable & long-acting HIV treatment

Long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression

News
23 August 2022